samedan logo
 
 
spacer
home > ict > winter 2019 > redefining the gold standard
PUBLICATIONS
International Clinical Trials

Redefining the Gold Standard

Adaptive clinical trials have risen in popularity and gained more attention since the FDA Critical Path Initiative (2004) and Critical Path Opportunity List (2006) called for innovative solutions to transform the way medicinal products are developed, evaluated, and manufactured. They are now being commonly used to quickly predict the likelihood of the success or failure of a drug in early stages of drug development.

The release of the FDA’s draft guidance in 2010 on “adaptive design clinical trials for drugs and biologics” provided a suggested framework for designing such studies and for using them to make decisions that would allow the innovator to “fail early.” EMA’s Committee for Medicinal Products for Human Use released a similar draft in 2006 (1).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Chitra Lele is Chief Scientific Officer at Sciformix, a Covance Company, with over 20 years of experience in the healthcare industry. She has been part of the company’s leadership from its inception and has been instrumental in establishing and growing the organisation. Prior to Sciformix, Chitra was Executive Director responsible for Indian operations of Pfizer Global R&D. With a PhD in statistics from Stanford University, US, her prior experience includes work as a biostatistician in cancer epidemiology at both Stanford and University of California, US.

Dr Ritu Budania is a Drug Safety Physician for global medical safety operations at Sciformix, a Covance Company. She completed her MBBS from Topiwala National Medical College, India, and MD Pharmacology from Government Medical College, India. Ritu has assisted in preparing ‘Desk View Clinical Trials in India’ for the WHO and prepared signal reports for Pharmacovigilance Programme of India (PvPI). She was in charge of the adverse drug monitoring centre under PvPI, at King Edward Memorial Hospital, India. Ritu has expertise in pharmacovigilance, clinical pharmacology, medical writing, clinical research, and clinical trials. She is also an experienced industry guest speaker in the subject of pharmacology.
Print this page
Send to a friend
Privacy statement
News and Press Releases

Joining forces against SARS-CoV-2

Laupheim, Germany and Milford, MA, USA, October 08, 2020 - Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, today announced an agreement to serve as CDMO partner for BioNTech. As an initial project, Rentschler Biopharma will be responsible for key aspects of cGMP (current good manufacturing practice) drug substance manufacturing of BNT162b2, the mRNA-based vaccine against SARS-CoV-2 that is being developed by Pfizer and BioNTech, and is currently in a global Phase 3 clinical trial.
More info >>

White Papers

Convergence in the Pharmaceutical Market

PCI Pharma Services

Convergence is currently playing a large part in the growth of the pharmaceutical market. The need for convergence is due to many factors including the declining economy and high competition within the sector. There are many convergences within this sector to date; these include the convergence of food based products with medical and health products and the convergence of prescription drugs to over the counter (OTC) products. Although convergence is helping the pharmaceutical industry expand and develop, it also poses some challenges; these include the regulatory outlook and counterfeiting.
More info >>

 
Industry Events

Clinical Operations in Oncology Trials West Coast

17-18 November 2020, Hilton San Francisco Airport Bayfront

Clinical Operations in Oncology Trials West Coast will be returning this April for another 2 day event full of thought-provoking presentations, discussions and roundtables. This years' conference highlights include the high-level, interactive immuno-oncology discussion panel where specialists from Shasta Bio Ventures, Abbvie and BeiGene shared their top tips on how to run successful and impactful immuno-oncology studies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement